Onward Medical NV (CHIX:ONWDB) Revenue: €3.78 Mil (TTM As of Dec. 2025)


CHIX:ONWDB Onward Medical NV CHIX:ONWDB
37 GF Score
Price €6.12
GF Value €319.28
! 4 Warning Signs
View Full Analysis

What is Onward Medical NV Revenue?

Onward Medical NV CHIX:ONWDB 37 Revenue is €3.78 Mil as of Dec. 2025. GuruFocus rates CHIX:ONWDB with a GF Score™ of 37/100 and a GF Value™ of €319.28. The stock has 4 warning signs investors should review.

Onward Medical NV's revenue for the six months ended in Dec. 2025 was €2.75 Mil. Its revenue for the trailing twelve months (TTM) ended in Dec. 2025 was €3.78 Mil. Onward Medical NV's Revenue per Share for the six months ended in Dec. 2025 was €0.06. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €0.08.

During the past 12 months, the average Revenue per Share Growth Rate of Onward Medical NV was 1520.00% per year. During the past 3 years, the average Revenue per Share Growth Rate was 200.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 9 years, Onward Medical NV's highest 3-Year average Revenue per Share Growth Rate was 200.00% per year. The lowest was 200.00% per year. And the median was 200.00% per year.


Onward Medical NV  (CHIX:ONWDb) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Onward Medical NV Revenue Related Terms


Onward Medical NV Revenue Historical Data

* Premium members only.

The historical data trend for Onward Medical NV's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Onward Medical NV Revenue Chart

Onward Medical NV Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Revenue
Get a 7-Day Free Trial Premium Member Only 0.00 0.10 0.07 0.23 3.78

Onward Medical NV Semi-Annual Data
Dec17 Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.07 0.00 0.23 1.04 2.75

CHIX:ONWDB vs VRTX, REGN, ALNY: Revenue Comparison

For the Biotechnology subindustry, Onward Medical NV's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Onward Medical NV Revenue vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Onward Medical NV's Revenue distribution charts can be found below:

* The bar in red indicates where Onward Medical NV's Revenue falls into.


CHIX:ONWDB
37GF Score
Onward Medical NV CHIX:ONWDB
Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Onward Medical NV Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €3.78 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Revenue →
What does a Revenue of €3.78 Mil mean?
Onward Medical NV (CHIX:ONWDB) has a Revenue of €3.78 Mil as of Dec. 2025. Revenue is the total amount a company generates as sales through its operations. View historical data on Onward Medical NV and its competitors.
Is Onward Medical NV's Revenue too high?
Onward Medical NV's current Revenue is €3.78 Mil. Overall, Onward Medical NV has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Onward Medical NV's Revenue compare to VRTX and REGN?
Onward Medical NV's Revenue of €3.78 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Biotechnology company?
A good Revenue depends on the Biotechnology industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Onward Medical NV and its competitors. Onward Medical NV's current Revenue is €3.78 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Onward Medical NV stock overvalued right now?
Onward Medical NV (CHIX:ONWDB) has a current Revenue of €3.78 Mil. The stock's GF Value™ is €319.28, compared to a current price of €6.12 — trading 98.1% below its estimated fair value. The current Revenue is €3.78 Mil. Onward Medical NV's overall GF Score™ is 37/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Onward Medical NV (CHIX:ONWDB), the current Revenue is €3.78 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Onward Medical NV (CHIX:ONWDB) Overvalued in 2026?

Based on GuruFocus' analysis, Onward Medical NV stock appears to be undervalued. The current stock price of €6.12 is trading 98.1% below its estimated GF Value™ of €319.28.

Key valuation signals for CHIX:ONWDB:

  • Revenue: €3.78 Mil
  • GF Value™: €319.28 vs. price of €6.12 (98.1% below fair value)
  • GF Score™: 37/100 with 4 warning signs

No single metric tells the full story. See the CHIX:ONWDB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Onward Medical NV Business Description

Address Schimmelt 2, Eindhoven, NH, NLD, NL-5656
Onward Medical NV is developing and commercializing therapies to enable functional recovery for people with Spinal Cord Injury (SCI). The company's technology platforms are based on ONWARD ARC Therapy (ARC Therapy), targeted, programmed electrical stimulation of the spinal cord designed to restore movement, independence, and health in people with SCI.
37GF Score

Get the complete analysis for CHIX:ONWDB

Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.12
Price
€319.28
GF Value